These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

100 related items for PubMed ID: 8393388

  • 1. Phase II study of 4'-iodo-4'-deoxydoxorubicin in non-resectable non-small-cell lung cancer.
    Sørensen JB, Stenbygaard L, Drivsholm L, Dombernowsky P, Hansen HH.
    Cancer Chemother Pharmacol; 1993; 32(5):399-402. PubMed ID: 8393388
    [Abstract] [Full Text] [Related]

  • 2. Clinical cardiotoxicity of esorubicin (4'-deoxydoxorubicin,DxDx): prospective studies with serial gated heart scans and reports of selected cases. A Cancer and Leukemia Group B report.
    Ringenberg QS, Propert KJ, Muss HB, Weiss RB, Schilsky RL, Modeas C, Perry MC, Norton L, Green M.
    Invest New Drugs; 1990 May; 8(2):221-6. PubMed ID: 2166722
    [Abstract] [Full Text] [Related]

  • 3. Broad phase II and pharmacokinetic study of methoxy-morpholino doxorubicin (FCE 23762-MMRDX) in non-small-cell lung cancer, renal cancer and other solid tumour patients.
    Bakker M, Droz JP, Hanauske AR, Verweij J, van Oosterom AT, Groen HJ, Pacciarini MA, Domenigoni L, van Weissenbruch F, Pianezzola E, de Vries EG.
    Br J Cancer; 1998 May; 77(1):139-46. PubMed ID: 9459159
    [Abstract] [Full Text] [Related]

  • 4. Phase II trial of 4' deoxydoxorubicin (DXDX) for unresectable non-small cell bronchogenic carcinoma. An Illinois Cancer Council study.
    Rose C, Lad TE, Kilton LJ, Schor J, Rosen ST, Rossof AH, Blough RR, Johnson CM.
    Invest New Drugs; 1990 Feb; 8(1):97-9. PubMed ID: 2160920
    [Abstract] [Full Text] [Related]

  • 5. Phase II studies of 4'-iodo-4'-deoxydoxorubicin in advanced non-small cell lung, colon and breast cancers.
    Sessa C, Calabresi F, Cavalli F, Cerny T, Liati P, Skovsgaard T, Sorio R, Kaye SB.
    Ann Oncol; 1991 Feb; 2(10):727-31. PubMed ID: 1666296
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Phase II study of carboplatin in untreated, inoperable non-small-cell lung cancer.
    Gatzemeier U, Heckmayr M, Hossfeld DK, Zschaber R, Achterrath W, Lenaz L.
    Cancer Chemother Pharmacol; 1990 Feb; 26(5):369-72. PubMed ID: 2170044
    [Abstract] [Full Text] [Related]

  • 9. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
    Colón-Otero G, Marschke R, Camoriano JK, Sorensen JM, Sloan JA, Richardson RL.
    Cancer J Sci Am; 1997 Feb; 3(5):297-302. PubMed ID: 9327154
    [Abstract] [Full Text] [Related]

  • 10. Phase II study of high-dose epirubicin and etoposide in advanced non-small cell lung cancer.
    Smit EF, Piers DA, Postmus PE.
    Eur J Cancer; 1992 Feb; 28A(12):1965-7. PubMed ID: 1329882
    [Abstract] [Full Text] [Related]

  • 11. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
    Dhingra K, Frye D, Newman RA, Walters R, Theriault R, Fraschini G, Smith T, Buzdar A, Hortobagyi GN.
    Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
    [Abstract] [Full Text] [Related]

  • 12. Phase II trial of high-dose liposome-encapsulated doxorubicin with granulocyte colony-stimulating factor in metastatic breast cancer. TLC D-99 Study Group.
    Shapiro CL, Ervin T, Welles L, Azarnia N, Keating J, Hayes DF.
    J Clin Oncol; 1999 May; 17(5):1435-41. PubMed ID: 10334528
    [Abstract] [Full Text] [Related]

  • 13. A phase-II clinical trial of 4'-epi-doxorubicin in advanced solid tumors.
    Martoni A, Giovannini M, Tomasi L, Camaggi CM, Bellanova B, Monetti N, Rossini G, Tarquinii M, Martini A, Pannuti F.
    Cancer Chemother Pharmacol; 1984 May; 12(3):179-82. PubMed ID: 6584236
    [Abstract] [Full Text] [Related]

  • 14. Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial.
    Chia S, Clemons M, Martin LA, Rodgers A, Gelmon K, Pond GR, Panasci L.
    J Clin Oncol; 2006 Jun 20; 24(18):2773-8. PubMed ID: 16682726
    [Abstract] [Full Text] [Related]

  • 15. Detection of doxorubicin cardiotoxicity in patients with sarcomas by indium-111-antimyosin monoclonal antibody studies.
    Carrió I, Lopez-Pousa A, Estorch M, Duncker D, Berná L, Torres G, de Andrés L.
    J Nucl Med; 1993 Sep 20; 34(9):1503-7. PubMed ID: 8355070
    [Abstract] [Full Text] [Related]

  • 16. Cisplatin, vindesine, mitomycin-C and 13-cis retinoic acid in the treatment of advanced non small cell lung cancer. A phase II pilot study.
    Recchia F, Sica G, De Filippis S, Rosselli M, Saggio G, Guerriero G, Pompili P, Rea S.
    Anticancer Res; 2000 Sep 20; 20(3B):1985-90. PubMed ID: 10928138
    [Abstract] [Full Text] [Related]

  • 17. [A randomized phase II trial of docetaxel and doxorubicin in treatment for patients with non-small-cell lung cancer who have failed previous platinum-based chemotherapy].
    Wang ZP, Sun Y, Zhang XR, Zhang MH, Wang XW, Yu XJ, Nan KJ, Li EX, Liu JW, Gao YJ, Guan XQ, Song SP, Sheng LJ, Wang DL, Wang ZX.
    Zhonghua Zhong Liu Za Zhi; 2008 Jun 20; 30(6):465-8. PubMed ID: 19024525
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Pegylated liposomal doxorubicin and trastuzumab as 1st and 2nd line therapy in her2/neu positive metastatic breast cancer: a multicenter phase II trial.
    Stickeler E, Klar M, Watermann D, Geibel A, Földi M, Hasenburg A, Gitsch G.
    Breast Cancer Res Treat; 2009 Oct 20; 117(3):591-8. PubMed ID: 19156515
    [Abstract] [Full Text] [Related]

  • 20. Pirarubicin in advanced non-small cell lung cancer. A trial of the Phase I/II Study Group of the Association for Medical Oncology of the German Cancer Society.
    Drings P, Günther IU, Gatzemeier U, Berdel W, Stahl M, Salewski E, Edler L.
    Onkologie; 1990 Jun 20; 13(3):180-4. PubMed ID: 2168533
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.